drugset / Trial / NCT01582490
Study of EXPAREL in Patients Undergoing Breast Augmentation
Non-randomizedSingle-groupOpen-labelTreatment
Summary
This is a Phase 4, prospective, open-label, non-randomized, sequential study with two treatment groups differing only in the technique used for EXPAREL administration (instillation or infiltration).
Timeline
- Start
- 2012-04
- Primary completion
- 2012-11
- Completion
- 2012-11
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Bupivacaine | Other / unclassified | 266 mg | Other |
Indications
No indication recorded.